Findings

What do systematic reviews say?

64 questions · 64 findings · 16 reviews · Musculoskeletal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 19 · 29.7%GRADE not reported 2 · 3.1%Very low 2 · 3.1%Low 17 · 26.6%Moderate 16 · 25%High 8 · 12.5%

Intervention not reported

ACR 50% improvement ‐ not measured · patients with treating rheumatoid arthritis

The review found no eligible studies for this question.

1 finding from 1 review

Herbal therapy for treating rheumatoid arthritis 2011 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

ACR 50% improvement ( · patients with Rheumatoid arthritis

The intervention showed no clear difference in ACR 50% improvement ( (low certainty).

1 finding from 1 review

Herbal therapy for treating rheumatoid arthritis 2011 · Cochrane Headline outcomes only
RR 11.92 [0.73, 193.38]
1 study · 23 participants
Low

Intervention not reported

ACR‐50 · patients with rheumatoid arthritis

1 finding from 1 review

Balance training (proprioceptive training) for patients with rheumatoid arthritis 2010 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + DMARDs/biologic

ACR50% improvement criteria · patients with rheumatoid arthritis

Tocilizumab 8 mg/kg + MTX/DMARD leads to higher ACR50% improvement criteria compared with placebo + MTX/DMARD (high certainty).

1 finding from 1 review

Tocilizumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 3.17 [2.72, 3.67]
4 studies · 2063 participants
High

Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX

ACR 50% improvement · patients with rheumatoid arthritis

Golimumab 50 mg every 4 weeks + MTX leads to higher ACR50 compared with placebo + MTX (high certainty).

1 finding from 1 review

Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 2.57 [1.34, 4.94]
4 studies · 919 participants
High

MTX combination vs MTX monotherapy

ACR 50 response of DMARDs naive patients Number of responders · patients with rheumatoid arthritis

MTX combination showed no clear difference in ACR 50 response of DMARDs naive patients Number of responders compared with MTX monotherapy (low certainty).

1 finding from 1 review

Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
RR 1.76 [0.64, 4.85]
2 studies · 127 participants
Low

MTX combination vs MTX monotherapy

ACR 50 response of MTX inadequate responders number of responders · patients with rheumatoid arthritis

MTX combination probably leads to higher ACR 50 response of MTX inadequate responders number of responders compared with MTX monotherapy (moderate certainty).

1 finding from 1 review

Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
RR 4.54 [2.51, 8.2]
3 studies · 404 participants
Moderate

MTX combination vs MTX monotherapy

ACR 50 response of non‐MTX DMARDs inadequate responders number of responders · patients with rheumatoid arthritis

MTX combination showed no clear difference in ACR 50 response of non‐MTX DMARDs inadequate responders number of… compared with MTX monotherapy (moderate certainty).

1 finding from 1 review

Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
RR 1.68 [0.94, 2.99]
2 studies · 158 participants
Moderate

MTX combination vs MTX monotherapy

Withdrawals due to adverse events · patients with rheumatoid arthritis

It is very uncertain whether MTX combination changes withdrawal due to adverse reactions (Pooled across regimens) number… compared with MTX monotherapy (very low certainty).

1 finding from 1 review

Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease modifying anti‐rheumatic… 2010 · Cochrane Headline outcomes only
RR 1.59 [1.2, 2.12]
17 studies · 1624 participants
Very low

Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic

ACR 50% improvement · patients with rheumatoid arthritis

Abatacept (2 and 10mg/kg) + DMARDs/biologic probably leads to higher ACR 50% improvement compared with placebo + DMARDs/biologic (moderate certainty).

1 finding from 1 review

Abatacept for rheumatoid arthritis 2009 · Cochrane Headline outcomes only
RR 2.21 [1.73, 2.82]
3 studies · 993 participants
Moderate

Leflunomide vs placebo, 6 months

ACR 50 response at 6 months · patients with rheumatoid arthritis in adults

Summary of findings: leflunomide leads to higher ACR 50 response at 6 months compared with placebo, 6 months (high certainty).

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
RR 2.32 [1.32, 4.05]
1 study · 221 participants
High

Summary of findings: leflunomide + methotrexate vs methotrexate

ACR 50% improvement · patients with rheumatoid arthritis in adults

Summary of findings: leflunomide + methotrexate leads to higher ACR 50 at 6 months compared with methotrexate, 6 months (high certainty).

1 finding from 1 review

Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
RR 4.35 [2.09, 9.03]
1 study · 263 participants
High

Posterior cruciate ligament retention vs sacrifice (all types of arthroplasty designs)

Performance based measures ‐ Range of motion (possible range 0 (worst) to 140 (maximal) degrees) · Patients receiving total knee arthroplasty with or without posterior stabilised design for the treatment of osteoarthritis

1 finding from 1 review

Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating osteoarthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Posterior cruciate ligament retention vs sacrifice (using the same arthroplasty design)

Survival rate of the implant (Revision surgery reported) · Patients receiving total knee arthroplasty with or without resection of the posterior cruciate ligament for the treatment of osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating osteoarthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Posterior cruciate ligament retention vs sacrifice (using the same arthroplasty design)

Health related quality of life measures and functional measures with validated instruments (WOMAC, range 0‐100, higher scores indicate worse pain, stiffness and functional limitations) · Patients receiving total knee arthroplasty with or without resection of the posterior cruciate ligament for the treatment of osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating osteoarthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Posterior cruciate ligament retention vs sacrifice (using the same arthroplasty design)

Global assessment (patient) Patient satisfaction on scale 0 (not at all satisfied) to 10 (completely satisfied) · Patients receiving total knee arthroplasty with or without resection of the posterior cruciate ligament for the treatment of osteoarthritis

1 finding from 1 review

Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating osteoarthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Posterior cruciate ligament retention vs sacrifice (using the same arthroplasty design)

Complications · Patients receiving total knee arthroplasty with or without resection of the posterior cruciate ligament for the treatment of osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating osteoarthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Posterior cruciate ligament retention vs sacrifice (using the same arthroplasty design)

Re‐operation rate (not involving implant change, short and long term) · Patients receiving total knee arthroplasty with or without resection of the posterior cruciate ligament for the treatment of osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating osteoarthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Posterior cruciate ligament retention vs posterior stabilised sacrifice

1 finding from 1 review

Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating osteoarthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Posterior cruciate ligament retention vs posterior stabilised sacrifice

Knee pain Knee Society Score, sub score pain (possible range 0 (severe pain) ‐ 50 (no pain) points) · Patients receiving total knee arthroplasty with or without posterior stabilised design for the treatment of osteoarthritis

1 finding from 1 review

Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating osteoarthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate